Determining magnitude of benefit from poly(ADP-ribose) polymerase inhibitors in prostate cancer

References

• Sung H , FerlayJ, SiegelRLet al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Gillessen S , BossiA, DavisIDet al. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur. J. Cancer185, 178–215 (2023).
   PubMed Web of Science ®Google Scholar
• Abida W , ArmeniaJ, GopalanAet al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis. Oncol.1, 1–16 (2017).
   Web of Science ®Google Scholar
• Robinson D , Van AllenEM, WuYMet al. Integrative clinical genomics of advanced prostate cancer. Cell161(5), 1215–1228 (2015).
   PubMed Web of Science ®Google Scholar
• Patel AG , SarkariaJN, KaufmannSH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc. Natl Acad. Sci. USA108(8), 3406–3411 (2011).
   PubMed Web of Science ®Google Scholar
• Teyssonneau D , MargotH, CabartMet al. Prostate cancer and PARP inhibitors: progress and challenges. J. Hematol. Oncol.14(1), 51 (2021).
   PubMed Web of Science ®Google Scholar
• Abida W , PatnaikA, CampbellDet al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J. Clin. Oncol.38(32), 3763 (2020).
   PubMed Web of Science ®Google Scholar
• De Bono J , MateoJ, FizaziKet al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med.382(22), 2091–2102 (2020).
   PubMed Web of Science ®Google Scholar
• Agarwal N , AzadAA, CarlesJet al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancetdoi:10.1016/S0140-6736(23)01055-3 (2023) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Chi KN , RathkopfD, SmithMRet al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J. Clin.Oncol.41(18), 3339–3351 (2023).
   PubMed Web of Science ®Google Scholar
• Clarke N , WiechnoP, AlekseevBet al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol.19(7), 975–986 (2018).
   PubMed Web of Science ®Google Scholar
• Clarke NW , ArmstrongAJ, Thiery-VuilleminAet al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid.1(9), (2022).
   PubMedGoogle Scholar
• Clarke NW , ArmstrongAJ, Thiery-VuilleminAet al. Final overall survival (OS) in PROpel: abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol.41(Suppl. 6), LBA16–LBA16 (2023).
   Google Scholar
• Schiewer MJ , GoodwinJF, HanSet al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov.2(12), 1134–1149 (2012).
   PubMed Web of Science ®Google Scholar
• Polkinghorn WR , ParkerJS, LeeMXet al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov.3(11), 1245–1253 (2013).
   PubMed Web of Science ®Google Scholar
• Li L , KaranikaS, YangGet al. Androgen receptor inhibitor-induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci. Sig.10(480), eaam7479 (2017).
   PubMed Web of Science ®Google Scholar
• Li Y , ZhaoZ, AiLet al. Discovering a qualitative transcriptional signature of homologous recombination defectiveness for prostate cancer. iScience24(10), 103135 (2021).
   PubMed Web of Science ®Google Scholar
• Lotan TL , KaurHB, SallesDCet al. Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. Mod. Pathol.34(6), 1185–1193 (2021).
   PubMed Web of Science ®Google Scholar
• Mateo J , CarreiraS, SandhuSet al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med.373(18), 1697–1708 (2015).
   PubMed Web of Science ®Google Scholar
• Mateo J , PortaN, BianchiniDet al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol.21(1), 162–174 (2020).
   PubMed Web of Science ®Google Scholar
• Hussain MHA , KocherginskyM, AgarwalNet al. BRCAAWAY: a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects. J. Clin. Oncol.40(Suppl. 16), S5018–S5018 (2022).
   Google Scholar
• Matsubara N , DeBono J, OlmosDet al. Olaparib efficacy in patients with metastatic castration-resistant prostate cancer and BRCA1, BRCA2, or ATM alterations identified by testing circulating tumor DNA. Clin. Cancer Res.29(1), 92–99 (2023).
   PubMed Web of Science ®Google Scholar
• Abida W , CampbellD, PatnaikAet al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 Study. Clin. Cancer Res.26(11), 2487–2496 (2020).
   PubMed Web of Science ®Google Scholar
• Fizazi K , PiulatsJM, ReaumeMNet al. Rucaparib or physician's choice in metastatic prostate cancer. N. Engl. J. Med.388(8), 719–732 (2023).
   PubMed Web of Science ®Google Scholar
• Smith MR , ScherHI, SandhuSet al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol.23(3), 362–373 (2022).
   PubMed Web of Science ®Google Scholar
• Chi KN , FleshnerN, ChiuriVEet al. Niraparib with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer: phase II QUEST study results. Oncologist28(5), e309–e312 (2023).
   PubMed Web of Science ®Google Scholar
• Sandhu S , AttardG, OlmosDet al. Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. J. Clin. Oncol.40(Suppl. 16), S5020–S5020 (2022).
   Web of Science ®Google Scholar
• De Bono JS , MehraN, ScagliottiGVet al. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncol.22(9), 1250–1264 (2021).
   PubMed Web of Science ®Google Scholar